In oncology, there’s something called the ‘kiss of death #shorts
29 Mar 2026 · 0 min
0:20
In this YouTube short, Dr. Dino Prato critiques the one‑size‑fits‑all approach of standard oncology, explaining that the microsatellite‑stability (MSS) label is often treated as a “kiss of death” because it disqualifies patients from receiving PD‑1 inhibitor therapy. He points out that conventional care relies on a limited set of roughly 24 data points, which can overlook therapeutic opportunities. By contrast, precision oncology leverages a vastly broader molecular profile—over a thousand data points—enabling custom drug design‑build and tailored immunotherapy strategies that can change patient eligibility and outcomes.
